MIF-1 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
MIF-1 (Pro-Leu-Gly-NH2 (Melanocyte-inhibiting factor-1)) is researched primarily for antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation. Unique as an allosteric dopamine modulator rather than agonist — enhances endogenous dopamine signaling without directly activating receptors, a mechanism distinct from most dopaminergic drugs. It belongs to the Neuropeptide, dopamine receptor modulator category of compounds.
What Is MIF-1?
MIF-1 (Pro-Leu-Gly-NH2 (Melanocyte-inhibiting factor-1)) is a Neuropeptide, dopamine receptor modulator. Endogenous tripeptide derived from cleavage of oxytocin, produced primarily by the hypothalamus.
Unique as an allosteric dopamine modulator rather than agonist — enhances endogenous dopamine signaling without directly activating receptors, a mechanism distinct from most dopaminergic drugs. It has attracted significant research interest for its potential effects on antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation.
How Does MIF-1 Produce These Benefits?
Acts as a positive allosteric modulator of D2 and D4 dopamine receptors while simultaneously blocking opioid receptor activation. Inhibits release of alpha-MSH and potentiates melatonin activity, creating a complex neurochemical profile affecting mood, motor function, and reward signaling.
This multi-pathway activity is why MIF-1 shows potential across several different applications rather than being limited to a single use case.
Can MIF-1 Help With Antidepressant Effects?
Research suggests MIF-1 may support antidepressant effects through its neuropeptide, dopamine receptor modulator activity. Extensively studied in animal models showing antidepressant and nootropic effects through multiple neurotransmitter systems. Multiple peer-reviewed studies from 1980s-1990s. No human clinical trials.
Protocols targeting antidepressant effects typically use 1-10 mg administered once daily for not established; short protocols in research.
Can MIF-1 Help With Nootropic Enhancement?
Research suggests MIF-1 may support nootropic enhancement through its neuropeptide, dopamine receptor modulator activity. Extensively studied in animal models showing antidepressant and nootropic effects through multiple neurotransmitter systems. Multiple peer-reviewed studies from 1980s-1990s. No human clinical trials.
Protocols targeting nootropic enhancement typically use 1-10 mg administered once daily for not established; short protocols in research.
Can MIF-1 Help With Anti-Parkinsonian Action?
Research suggests MIF-1 may support anti-Parkinsonian action through its neuropeptide, dopamine receptor modulator activity. Extensively studied in animal models showing antidepressant and nootropic effects through multiple neurotransmitter systems. Multiple peer-reviewed studies from 1980s-1990s. No human clinical trials.
Protocols targeting anti-Parkinsonian action typically use 1-10 mg administered once daily for not established; short protocols in research.
Can MIF-1 Help With Dopamine Modulation?
Research suggests MIF-1 may support dopamine modulation through its neuropeptide, dopamine receptor modulator activity. Extensively studied in animal models showing antidepressant and nootropic effects through multiple neurotransmitter systems. Multiple peer-reviewed studies from 1980s-1990s. No human clinical trials.
Protocols targeting dopamine modulation typically use 1-10 mg administered once daily for not established; short protocols in research.
Can Stacking Enhance MIF-1 Benefits?
Pairs with dopamine-enhancing compounds (L-DOPA) to amplify dopaminergic effects through allosteric modulation.
See our MIF-1 stacking guide for detailed combination protocols.
What Is the Bottom Line on MIF-1 Benefits?
MIF-1 is researched for antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation. The evidence base includes: Extensively studied in animal models showing antidepressant and nootropic effects through multiple neurotransmitter systems. Multiple peer-reviewed studies from 1980s-1990s. No human clinical trials.
MIF-1 is not fda-approved. research chemical. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
MIF-1 : Benefits, Dosage, Side Effects & Research
Related Reading
- MIF-1 Dosage Guide
- MIF-1 Side Effects
- MIF-1 Stacking Guide
- MIF-1 Cycle Guide
- MIF-1 Research
- Dihexa Complete Guide
Calculate Your MIF-1 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for MIF-1.
Open Calculator →Research-Grade Sourcing
If you're going to research MIF-1, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is MIF-1?
MIF-1 (Pro-Leu-Gly-NH2 (Melanocyte-inhibiting factor-1)) is a Neuropeptide, dopamine receptor modulator. Endogenous tripeptide derived from cleavage of oxytocin, produced primarily by the hypothalamus. It is researched for antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation.
What is the recommended MIF-1 dosage?
Common dosages: 1-10 mg administered once daily via subcutaneous injection (poorly active orally). Cycle length: not established; short protocols in research. Half-life: resistant to bloodstream metabolism; crosses blood-brain barrier. Use our peptide calculator for exact reconstitution math.
What are the side effects of MIF-1?
Limited human data. Inverted U-curve response — loses efficacy at very high doses. No serious adverse effects documented.
Is MIF-1 safe?
MIF-1 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical. All research should follow appropriate safety protocols.